Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

427
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
427
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

285
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
285
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Cancer Survival Analysis01:21

Cancer Survival Analysis

424
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
424
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

38
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current opinion: the OCEANIC trial journey: from failure to breakthrough?

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026
Same author

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.

Research and practice in thrombosis and haemostasis·2026
Same author

Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort.

Thrombosis research·2026
Same author

Thrombin generation and the pharmacodynamics of parenteral anticoagulants.

Pharmacological reviews·2026
Same author

Andexanet alfa for the reversal of anticoagulation: Dutch practice data.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Aug 26, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K

Evolving data on cardiovascular complications in cancer.

Ruth A L Willems1, Kristien Winckers2, Charlotte Biesmans3

  • 1Thrombosis Expert Center Maastricht and Department of Internal Medicine, Section Vascular Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.

Thrombosis Research
|October 10, 2022
PubMed
Summary

Cancer patients face higher cardiovascular risks due to shared factors and treatments. Effective prevention and treatment strategies are crucial for cancer survivors, as heart disease significantly impacts their survival and quality of life.

Keywords:
Antiplatelet therapyArterial thromboembolismCancerCardiovascular diseaseIschemic strokeMyocardial infarction

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

520
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Related Experiment Videos

Last Updated: Aug 26, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

520
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Area of Science:

  • Cardio-oncology
  • Oncology
  • Cardiology

Background:

  • Cancer and cardiovascular disease (CVD) are leading global causes of death.
  • Patients with cancer have an elevated risk of cardiovascular events, driving the field of cardio-oncology.
  • Shared risk factors, mechanisms, and genetics link cancer and CVD, with treatments like radiotherapy exacerbating cardiac risk.

Purpose of the Study:

  • To review current data on cardiovascular disease in cancer patients.
  • To highlight the significant contribution of CVD to mortality in cancer survivors.
  • To focus on atherothrombotic events, including myocardial infarction and ischemic stroke, in this population.

Main Methods:

  • Literature review of scientific studies and evolving data.
  • Analysis of the interplay between cancer, its treatments, and cardiovascular health.
  • Focus on specific cancer types where CVD is a major cause of death.

Main Results:

  • Cardiovascular disease is a major cause of mortality and morbidity in cancer survivors.
  • For certain cancers (e.g., breast, prostate), CVD accounts for approximately 50% of patient deaths.
  • Anticancer therapies, particularly radiotherapy, can increase cardiovascular risk.

Conclusions:

  • There is an urgent need for strategies to prevent and treat cardiovascular events in cancer patients and survivors.
  • Cardiovascular disease is a critical concern in the growing population of cancer survivors.
  • Understanding the link between cancer and CVD is essential for improving patient outcomes.